Press Release August 19, 2022

Medipost Acquires OmniaBio to Launch CDMO Business in North America

The Life Sciences team advised Medipost Co. in its strategic agreement with OmniaBio, Inc., a subsidiary of the Centre for Commercialization of Regenerative Medicine (CCRM).  Medipost acquired an equity interest in OmniaBio from CCRM for cash of CAD $30 million and is investing an additional CAD $60 million in Notes into OmniaBio. Once launched, OmniaBio will be the largest contract development and manufacturing organization (CDMO) business in Canada.

Medipost is registered on KOSDAQ and is a Korean pharmaceutical company specializing in the stem cell therapeutics field.

OmniaBio is a CDMO producing gene-modified cell therapies and viral vectors.

The Goodwin team was led by John J. Egan, Steven Green, Maggie Beale-Wirsing, Ashley Nguyen and Swetha Gopalakrishnan, with invaluable assistance from Larissa Pinho (Corporate/Life Sciences); Shane Albright (IP/Licensing), Reid Bagwell and Melissa Schwab Wright (Debt).

For more details, read OmniaBio’s press release and Medipost’s press release.